Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RNVS may have bottomed again, I went big on some purchases today. It may bounce around for a little while longer, but it should have another nice run.
Buying back some RNVS today, the chart seems to have good support from around $3.10 to $3.25(I'll be buying here all the way down to $3 if it goes there) RNVS should have another good run in its stock....GLTY
nice volume anyway; i think we're just getting started. Won't sell just yet!
Might open above 5.00 today
More good news for RNVS:
Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists
Tuesday April 10, 8:30 am ET
SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS - News), a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced an agreement with Pfizer Inc. (NYSE: PFE - News) to extend the term of the companies' worldwide collaboration to research, develop and commercialize small molecules that target the vanilloid receptor, VR1. This extension provides Renovis with additional research funding through June 30, 2008 and reflects the goal of Pfizer and Renovis to advance multiple, small molecule VR1 antagonists toward clinical development.
ADVERTISEMENT
The VR1 receptor is a member of a related group of ion channel proteins known as the transient receptor potential (TRP) family that mediate and influence cell signaling. Inhibitors of VR1 are predicted to be useful in the treatment of pain, urinary incontinence and other diseases and disorders.
"We partnered our VR1 program with Pfizer in June 2005 at a preclinical stage because we believed that safe and effective antagonists of VR1 could potentially address major medical needs in multiple therapeutic areas and we wanted to work with a partner capable of aggressively pursuing this broad potential with us," stated Corey S. Goodman, Ph.D., President and Chief Executive Officer of Renovis. "Since then, the collaboration has produced its first advanced candidate, which we expect to enter human testing in 2007, as well as several other small molecule VR1 antagonists that we hope to advance into IND-enabling studies and clinical development with Pfizer during the term of this extension."
"VR1 antagonists represent an enormous opportunity to help large numbers of patients who are poorly served by existing therapies," added Michael G. Kelly, Ph.D., Senior Vice President of Research and Development. "We are strongly committed to doing all that we can with Pfizer to deliver on this promise."
Under the terms of the extension, Pfizer will continue to fund all aspects of the collaboration including the research and preclinical development efforts at Renovis through June 30, 2008. Other terms of the collaboration and licensing agreements between Pfizer and Renovis have not been changed.
2007 Financial Guidance
Financial projections involve a high level of uncertainty due, among many factors, to the variability involved in predicting requirements of drug discovery and clinical development activities and the potential for Renovis to enter into new licensing agreements or strategic collaborations. We plan to update financial guidance for 2007, as necessary, when we release results for each quarter or upon the announcement of material corporate events.
For the year ending December 31, 2007, the Company has updated its financial guidance as previously announced in conjunction with its results for the year ended December 31, 2007, to give effect to the extension of its collaboration with Pfizer. The Company now expects:
-- total contract revenue from existing agreements of $5.3 million to $9.8
million; and
-- total operating expenses of $28.0 million to $32.0 million, excluding
non-cash, stock-based compensation to be recognized in accordance with
SFAS No. 123R and $1.1 million in restructuring expense that we
recorded in the first quarter of 2007.
About Renovis
Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on purinergic receptors for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury.
For additional information about the company, please visit www.renovis.c
RNVS has had some nice steady action in the past month & may be ready to break that old late Jan high of $3.73(still holding)
let's hope to get some news soon!!
Noticed that RNVS was picked on the charting site (stocktiger.com) The site has a very good track record and is know for finding early chart breakouts.
certainly, but no news yet thats strange. my average is 3,83 so i hope it continius tomorow.
(sorry my English isn't very good, i'm from Belgium).
Have a nice evening
Renovis Announces Management Changes
3 Jan 2007, 09:01am ET
E-mail or Print this story
- - - - -
SOUTH SAN FRANCISCO, Calif., Jan 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Renovis, Inc. (NASDAQ:RNVS), today announced changes in the Company's management team. Donald R. Joseph, Senior Vice President, Corporate Development and General Counsel, is leaving the Company to take a senior operations position with a private entity in the healthcare field. In addition, Tito A. Serafini, Ph.D., Vice President, Technology, is leaving Renovis to pursue another business interest. Dr. Serafini has agreed to assist the Company in a consulting role. These changes are effective immediately.
"I would like to thank Don and Tito for their service and contributions to Renovis," said Corey S. Goodman, Ph.D., President and Chief Executive Officer. "As one of the Company's co-founders, Tito has been a key contributor in a wide variety of operational roles and activities at Renovis since 2000, and we wish him well in his next endeavor. Don has been an effective leader of our corporate development activities during 2006, in addition to building our legal department. He has decided to apply his talents in a new direction and we wish him the best." Dr. Goodman continued, "Our strategic focus is to continue the development of our internal programs in neurological and inflammatory diseases while we explore additional opportunities to build our pipeline. Renovis is in a strong financial position and we are well situated to advance our internal programs toward the clinic."
The functions previously managed by Mr. Joseph and Dr. Serafini will be reassigned to other senior executives.
About Renovis
Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The company's proprietary research programs focus on purinergic receptors for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury.
For additional information about the company, please visit www.renovis.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Renovis cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the periodic reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 8, 2006, and our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 14, 2006. Renovis is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
SOURCE Renovis, Inc.
Greg Mann of Renovis, Inc., +1-650-266-1558, or gmann@renovis.com
http://www.prnewswire.com
New investor (Lampert) #msg-15567201 and now top management change http://biz.yahoo.com/prnews/070103/sfw069.html?.v=81
Buyout coming?
charts - 10 days and option charts that I thought were worth looking at. I picked up some of the April calls.
#msg-15203290
Buying some more RNVS...trading at cash & a nice bounce play. Another banged up small cap bio was bought today(PRCS)
Low risk/reward.
surf
i noticed ;o) bought mine at 3,85 average so i don't mind that it go's up
have a nice day
The stock is up
Lampert, Mark N -- ARNA only one I can find with his name personally
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001233840&owner=include&c...
New 13G
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=4544934
None on this list: http://www.nasdaq.com/asp/Holdings.asp?symbol=RNVS&selected=RNVS&page=holdingssummary
so new money
========================
ITEM 1(a).
NAME OF ISSUER:
Renovis, Inc. ("Renovis")
ITEM 1(b).
ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
Two Corporate Drive
South San Francisco, CA 94080
ITEM 2(a).
NAME OF PERSON FILING:
This Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):
(i)
Biotechnology Value Fund, L.P. ("BVF")
(ii) Biotechnology Value Fund II, L.P. ("BVF2")
(iii) BVF Investments, L.L.C. ("Investments")
(iv) Investment 10, L.L.C. ("ILL10")
(v) BVF Partners L.P. ("Partners")
(vi) BVF Inc. ("BVF Inc.")
ITEM 2(b).
ADDRESS OF PRINCIPAL BUSINESS OFFICE:
The principal business office of the persons comprising the group filing this Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.
ITEM 2(c).
CITIZENSHIP:
BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Investments: a Delaware limited liability company
ILL10: an Illinois limited liability company
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation
ITEM 2(d).
TITLE OF CLASS OF SECURITIES:
This Schedule 13G is being filed with respect to the common stock, par value $0.001 per share (the "Common Stock"), of Renovis. The Reporting Persons' percentage ownership of the Common Stock is based on 29,395,097 shares of the Common Stock being outstanding.
As of December 14, 2006, (i) BVF beneficially owns 508,180 shares of Common Stock; (ii) BVF2 beneficially owns 349,950 shares of Common Stock; (iii) Investments beneficially owns 1,344,158 shares of Common Stock; and (iv) ILL10 beneficially owns 149,312 shares of Common Stock. Beneficial ownership by Partners and BVF Inc. includes 2,351,600 shares of Common Stock.
ITEM 2(e).
CUSIP Number:
759885106
=========
AGREEMENT REGARDING JOINT FILING
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Investments, L.L.C., a Delaware limited liability company, Investment 10, L.L.C., an Illinois limited liability company, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the information required by Schedule 13G, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.
Dated: December 14, 2006
BIOTECHNOLOGY VALUE FUND, L.P.
By:
BVF Partners L.P., its general partner
By:
BVF Inc., its general partner
By:
/s/ MARK N. LAMPERT
--------------------------------------------------------------------------------
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By:
BVF Partners L.P., its general partner
By:
BVF Inc., its general partner
By:
/s/ MARK N. LAMPERT
--------------------------------------------------------------------------------
Mark N. Lampert
President
BVF INVESTMENTS, L.L.C.
By:
BVF Partners L.P., its manager
By:
BVF Inc., its general partner
By:
/s/ MARK N. LAMPERT
--------------------------------------------------------------------------------
Mark N. Lampert
President
INVESTMENT 10, L.L.C.
By:
BVF Partners L.P., its attorney-in-fact
By:
BVF Inc., its general partner
By:
/s/ MARK N. LAMPERT
--------------------------------------------------------------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By:
BVF Inc., its general partner
By:
/s/ MARK N. LAMPERT
--------------------------------------------------------------------------------
Mark N. Lampert
President
BVF INC.
By:
/s/ MARK N. LAMPERT
--------------------------------------------------------------------------------
Mark N. Lampert
President
Just bought into RNVS, I don't know how I missed this little biotech(plenty of cash)
surf
It would be nice if others with some insight on RNVS would come share their thoughts. I have been watching January calls for a possible entry, so some weakness in the stock is good for me... but I would be happy to see it move up
Had some late buying interest on RNVS today... and now some tricky business going on in after hours.... like somebody is trying to shake the tree or somesuch.... don't know... just odd...
sure. I think it is an area to buy.
Worm DR;
Care to editorialize on your thinking here? Okay, lot of short interest, but who would ever short a 3 dollar biotech at this price? Are you thinking this is a bottum?
steve
These two things don't seem to be compatible:
11/30/2006 (10:30 ET) BUYINS.NET: NTRZ, ONXX, RNVS, ADSOE Have Also Been Removed From Naked Short List Today - M2 Communications
11/27/2006 (16:20 ET) RNVS: Short Interest UP 4.3% to 5.9M in Nov 2006 - Knobias
=======================================================
Knobias link: http://www.knobias.com/individual/public/quote.htm?aff=IHUB&ticker=RNVS
11/27/2006 (12:59 ET) Businessnetwire.us: Amelot Grows Stronger with Agreement from Merlin Petroleum - M2 Communications
11/24/2006 (10:27 ET) (OTC PK: ECFL) Good News for Shareholders -- No Reverse Stock Split - Market Wire
11/24/2006 (09:47 ET) BUYINS.NET: MSEM, CKYS, RNVS, MLXO Have Been On BUYINS.NET Naked Short List For 13 Consecutive Trading Days - M2 Communications
11/22/2006 (14:55 ET) RNVS: New Form 4 Filed, Change in Beneficial Ownership - Edgar
11/22/2006 (06:07 ET) RNVS: mentioned in today's Wall Street Journal - Knobias
11/08/2006 (16:21 ET) RNVS: Jumps +4.49%; Vol +64%; Last 90 Min of Trading - Knobias
11/08/2006 (16:02 ET) RNVS: Filed New Form 10-Q, Quarterly Report - Edgar
11/08/2006 (14:06 ET) RNVS: Filed New Form SC 13G/A, Beneficial Ownership Disclosure - Edgar
11/07/2006 (09:03 ET) BUYINS.NET: CREL, GMO, PHI, RNVS, UTK, AACQ Have Been Added To Naked Short List Today - M2 Communications
11/06/2006 (13:00 ET) Stroke Treatments Reviewed by NeuroInvestment - Market Wire
11/03/2006 (17:18 ET) RNVS: New Form 4 Filed, Change in Beneficial Ownership - Edgar
11/02/2006 (10:05 ET) RNVS: New 52-Wk Low @ $3.220 dn 3.88% - Knobias
11/01/2006 (15:25 ET) RNVS: New 52-Wk Low @ $3.350 dn 4.56% - Knobias
10/30/2006 (20:44 ET) RNVS: New Form 4 Filed, Change in Beneficial Ownership - Edgar
10/30/2006 (09:18 ET) RNVS: Matrix Ups to Sell from Strong Sell; Analyst Notes - Knobias
10/27/2006 (18:12 ET) Corporate Announcement: Renovis - Wall Street Horizon
10/27/2006 (10:45 ET) RNVS: Volume Spike; 11% > 20-adsv, Stock +3.79% - Knobias
10/27/2006 (06:38 ET) RNVS: mentioned in today's Wall Street Journal - Knobias
10/26/2006 (23:31 ET) Renovis Drug Fails Trials, Development Halted - Investrend
10/26/2006 (14:38 ET) RNVS: S&P Ups to 3 STARS (Hold) from 1 STAR (Sell); Cuts Tgt to $5 vs $8; Analyst Notes - Knobias
10/26/2006 (11:35 ET) Hot Stocks to Watch for Thursday, October 26, 2006: Opening Doors for Major Future Business Relationship! - Market Wire
10/26/2006 (11:10 ET) Smallcapstockwatch.com: Practical Applications of Micro Fuel Cells Is Close at Hand; VIASPACE CEO Interviewed in Japan - Market Wire
10/26/2006 (10:27 ET) RNVS: Needham Cuts to Underperform from Buy - Knobias
NASDAQ Monthly Short Interest
RNVS - Renovis, Inc. - Common Stock
Month ShortInterest %Change AvgDailyVol DaystoCover
November 2006 5,854,285 4.28 3,914,490 1.50
October 2006 5,613,822 3.58 393,694 14.26
September 2006 5,420,011 8.56 198,018 27.37
August 2006 4,992,666 (11.59) 458,675 10.88
July 2006 5,646,998 (1.64) 207,780 27.18
June 2006 5,741,172 4.91 290,193 19.78
May 2006 5,472,495 7.13 160,678 34.06
April 2006 5,108,206 27.11 350,771 14.56
March 2006 4,018,684 9.99 575,840 6.98
February 2006 3,653,732 7.87 360,838 10.13
January 2006 3,387,099 1.98 250,201 13.54
December 2005 3,321,286 (9.88) 230,839 14.39
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
80
|
Created
|
11/27/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |